FDA Issues Warning about Vinpocetine for Women with Reproductive Potential

On Tuesday, June 4 the FDA issued a warning advising pregnant women and women who could become pregnant to not take dietary supplements containing vinpocetine due to possible reproductive safety risks. Read more about the FDA warning.

ACOG continues to recommend that obstetrician-gynecologists and other health care providers review all prescription and nonprescription medications during prepregnancy counseling, including nutritional supplements and herbal products that patients may not consider to be medication use but could affect reproduction and pregnancy (see Committee Opinion 762 for more information). Furthermore, obstetrician-gynecologists and other obstetric providers should ask about a patient’s medication use (including supplements, vitamins, herbs, or over-the-counter drugs) at the patient’s first prenatal visit as part of routine prenatal care (see Guidelines for Perinatal Care for more information).


American College of Obstetricians and Gynecologists
409 12th Street SW, Washington, DC  20024-2188
Mailing Address: PO Box 96920, Washington, DC 20024-9998